Navigation Links
WHO Launches Yellow Fever Initiative for West Africa

The World Health Organization (WHO) has launched a comprehensive immunization programme across 12 highest-risk countries in West Africa , and aimed at covering as many as 48 milllion people.

The initiative is being undertaken to counter the yellow fever, resurging in the region and is backed by a $ 58 million contribution from the GAVI Alliance.

The Alliance (formerly known as the Global Alliance for Vaccines and Immunisation) is a public-private partnership focused on increasing children's access to vaccines in poor countries. Partners include the GAVI Fund, national governments, UNICEF, WHO, The World Bank, the Bill & Melinda Gates Foundation, the vaccine industry, public health institutions and nongovernmental organizations (NGOs). The GAVI Fund provides resources for the Alliance programs.

Childhood immunisation is one of the best values in health care, providing tremendous benefit at very low cost. A child can be immunised for only $30. It is a near-perfect intervention, preventing disease before it is allowed to take root, protecting children when they are most vulnerable and providing them with a healthy start in life.

The GAVI alliance website notes - The Alliance addresses one of the worlds most glaring injustices: the inability of the poorest countries to provide vaccines for all of their children. Roughly one child in four does not receive any vaccinations. Of the 130 million children born each year, two to three million will die from vaccine-preventable diseases.

"The Yellow Fever Initiative will be able to vaccinate at-risk populations and thus quickly reduce the risk of devastating outbreaks that could otherwise threaten the region and the world," Mike Ryan, Director of the WHO Department of Epidemic and Pandemic Alert and Response said in Geneva, where the World Health Assembly is convened.

To prevent yellow fever infections from spreading into an epidemic, immunization coverage must
'"/>




Page: 1 2

Related medicine news :

1. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
2. Serum Institute Launches New Tetanus-Diphtheria Vaccine
3. Scottish Health Minister Launches Organ Donor Plan
4. Pfizer Launches Viagra For Lung Disease In UK
5. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
6. PM Launches Healthcare Foundation For India
7. African Union Launches A Programme On Acceleration of HIV Prevention
8. Yale School of Medicine Launches Telemonitoring Of Heart Failure Symptoms
9. Prince Harry Launches AIDS Charity In Memory Of Princess Diana
10. The British Medical Journal Launches A Health Website
11. APEC Launches Bird Flu Exercise
Post Your Comments:
(Date:10/3/2008)...- Inc. Magazine recently included,Connolly Consult...ing,private companies in the country. The list is ...segment of the economy -- America,s,independent-mi...ies,represent the backbone of the U.S. economy., ...03/NY36880LOGO ), Connolly Consulting,s consiste...
(Date:10/3/2008)... Discrimination; Recognizes,Importance of Mental H.../PRNewswire-USNewswire/ -- Mental Health,America t...approval of a,mental health parity legislation tha...ion against Americans with mental health and subst...lans., The legislation, which recognizes the impo...
(Date:10/3/2008)...search Foundation(R) Collection of, Bouquets to T...Research, LOS ANGELES, Oct. 3 /PRNewswire/ -- Tel...g only hand-arranged, hand-delivered floral,arrang...nth-long,collaboration with The City of Hope, John... Cancer Center in southern California and national...
(Date:10/3/2008)...- As the population ages, a big,question employers...e the,financial crunch of an illness?", In most c...eck to,paycheck and now need two incomes to provid... spouses becomes critically ill and unable to work...ut the healthy,employee/spouse is strained by the ...
Breaking Medicine News(10 mins):Health News:Connolly Consulting Makes the 2008 Inc. Magazine's List of America's 5000 Fastest Growing Companies 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 3Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 2Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 3Health News:Can Your Employees Survive the Financial Crunch of an Illness? 2
...who are overweight or obese have a greater risk of...sease, a new study by US and Australian researcher...s Jefferson University in Philadelphia and the Edi...Australia - say that being obese 'almost certainly...
...hers from Germany have discovered a novel, less in...nary veins. This technique, called ECG-gated cardi... associated with very few complications // . It is...ed diagnostic quality and treatment. A comparison...
...n cancer gel developer Peplin has said that it wou...st-action cancer cream since it was able to get an...ors for this purpose. The company based in Quee...05 compound as a treatment for actinic keratosis a...
...ube has been designed by scientists belonging to t...for delivering cells or molecules for treatment, t...ished in the Biomedical Microdevices. In the initi...ned box, but when heat is applied, the sides fold ...
Other Medicine News:Health News:Obesity could lead to Alzheimer's 2Health News:Nanocubes Designed For Delivering Cells 2
(Date:10/2/2008)... STOCKHOLM, October 2 /- Athera Biot...unced today that they have entered into a,collabor...cts for the,prevention or treatment of cardiovascu...lows the recent publication of work by Athera,scie...e of the Karolinska,Institutet. The research links...
(Date:10/2/2008)... Data Indicate Dual Modes of Action and Synergy...rstCall/ -- Access Pharmaceuticals, Inc.,(OTC Bull...eclinical,studies on Angiolix showing that by bloc...enic effect as well as a direct anti-proliferative...s of human breast cancer (MX-1),Angiolix had a si...
(Date:10/1/2008)...ta support the therapeutic potential of Amylin,s i...to obesity pharmacotherapy, SAN DIEGO, Oct. 1 /PR.... (Nasdaq: AMLN ) today announced that new data f...ed at the 2008 Annual Scientific Meeting of The,Ob...Society,s annual,meeting is one of the largest and...
(Date:10/1/2008)...Intermezzo(R) (zolpidem tartrate sublingual lozeng...ly for use in the middle of the night when ...sleep, PT. RICHMOND, Calif., Oct. 1 /PRNewswire/ ...ld specialty pharmaceutical company, announced tod...DA) to the U.S. Food and,Drug Administration (FDA)...
Breaking Medicine Technology:Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 2Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 3Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 4Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 6Experts discuss climate change during UH lecture series 5081 1Experts discuss climate change during UH lecture series 5081 2Telik Announces Receipt of Nasdaq Notice 7927 1Telik Announces Receipt of Nasdaq Notice 7927 2Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment 7926 1Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment 7926 2Army can boost mission success by better managing 5076 1Army can boost mission success by better managing 5076 2Army can boost mission success by better managing 5076 3Army can boost mission success by better managing 5076 4
...l 30, 2007 /PRNewswire-FirstCall/,-- , - Femara re...ungs, the brain or the bone which has a worse prog...ast , Newly published data in the May issue of Ann... after two years of post-surgical,therapy, postmen...cancer treated with Femara experienced 30 percent ...
...ation with the Centro de,Investigación M&ea...arra, Pamplona, Spain, is being presented at,Porph...erlands. , AMSTERDAM, the Netherlands, May 1st 200...eader in the field of human gene therapy,will tod...erapy to,treat acute intermittent porphyria (AIP) ...
Other Medicine Technology:Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 2Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 3Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 4Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 5Amsterdam Molecular Therapeutics BV to present preclinical,proof-of-concept data on its gene therapy AMT-020 to treat acute,intermittent porphyria 2Amsterdam Molecular Therapeutics BV to present preclinical,proof-of-concept data on its gene therapy AMT-020 to treat acute,intermittent porphyria 3
...) is the sulfate ester of DHEA, derived from sulfa... in adrenal and extradrenal tissues. DHEA is the m...nd is a precursor for testosterone and estrogen bi...nic activity, which for unsulfated DHEA has been e...
...ompetition principle and the microplate separation...e and a fixed amount of DHEA-S conjugated with hor... of a polyclonal DHEA-S antiserum coated onto the ...te is washed to stop the competition reaction. Hav...
Inquire
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM.
Medicine Products: